Table 1.
Patient baseline characteristics
| 6-week schedule |
5-week schedule |
Total |
|||
|---|---|---|---|---|---|
| Group 1 (n = 35) | Group 2 (n = 49) | Group 1 (n = 12) | Group 2 (n = 24) | (n = 120) | |
| Age, median (range), y | 66 (46-84) | 66 (43-78) | 62 (46-74) | 68 (61-76) | 66 (43-84) |
| Sex | |||||
| Female | 9 (26%) | 13 (27%) | 5 (42%) | 8 (33%) | 35 (29%) |
| Male | 26 (74%) | 36 (73%) | 7 (58%) | 16 (67%) | 85 (71%) |
| WHO PS | |||||
| 0 | 12 (34%) | 20 (41%) | 5 (42%) | 15 (63%) | 52 (43%) |
| 1 | 23 (66%) | 29 (59%) | 7 (58%) | 9 (37%) | 68 (57%) |
| MRC dyspnea score∗ | |||||
| 0 | 10 (31%) | 15 (33%) | 6 (50%) | 10 (42%) | 41 (36%) |
| 1 | 12 (38%) | 22 (48%) | 5 (42%) | 12 (50%) | 51 (45%) |
| 2 | 8 (25%) | 6 (13%) | 1 (8%) | 1 (4%) | 16 (14%) |
| 3 | 2 (6%) | 3 (7%) | 0 | 1 (4%) | 6 (5%) |
| Histology | |||||
| Adenocarcinoma | 12 (34%) | 14 (29%) | 2 (17%) | 5 (21%) | 33 (28%) |
| Squamous | 17 (49%) | 30 (61%) | 8 (67%) | 15 (63%) | 70 (58%) |
| Other NSCLC | 6 (17%) | 5 (10%) | 2 (17%) | 4 (17%) | 17 (14%) |
| Stage (UICC TNM, seventh edition) | |||||
| IIA | 0 | 0 | 0 | 0 | 0 |
| IIB | 0 | 6 (12%) | 0 | 1 (4%) | 7 (6%) |
| IIIA | 24 (69%) | 33 (67%) | 8 (67%) | 16 (67%) | 81 (68%) |
| IIIB | 11 (31%) | 10 (20%) | 4 (33%) | 6 (25%) | 31 (26%) |
| IV | 0 | 0 | 0 | 1 (4%) | 1 (1%) |
| GTV size, median (range), cm3 | 110 (14-602) | 94 (15-329) | 46 (21-164) | 105 (21-217) | 101 (14-602) |
Abbreviations: GTV = gross tumor volume; MRC = Medical Research Council; NSCLC = non-small cell lung cancer; UICC = Union Internationale Contre le Cancer; WHO PS = World Health Organization performance status.
∗
Baseline dyspnea scores available for 78 of 84 patients treated using the 6-week schedule.